What is Biohaven Pharmaceutical Holding Co Ltd (BHVN) stock price today?

Biohaven Pharmaceutical Holding Co Ltd (BHVN) currently trades at $9.59 per share. The stock has a market capitalization of $1.38B and a P/E ratio of —x.

Is BHVN stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Biohaven Pharmaceutical Holding Co Ltd has a Smart Value Score of 23/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -4.94.

Is Biohaven Pharmaceutical Holding Co Ltd financially healthy?

Biohaven Pharmaceutical Holding Co Ltd's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -4.94 places it in the distress.

BHVN

Biohaven Pharmaceutical Holding Co Ltd

NYSE: BHVN · HEALTHCARE · BIOTECHNOLOGY

$9.59

+4.24% today

Updated 2026-04-30

Market cap

$1.38B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-6.86

Dividend yield

—

52W range

$7 – $24

Volume

2.2M

Market cap

$1.38B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-6.86

Dividend yield

—

52W range

$7 – $24

Volume

2.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

4.8

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-4.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$22.35

+133.06%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

4 Strong Buy9 Buy5 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -4.94 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-130.67M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-570.28M	$-408.17M	$-846.42M	$-738.82M	$-145.56M
EPS	—	—	—	—	$-6.86
Free cash flow	$-338.76M	$-334.77M	$-586.50M	$-610.15M	$-130.67M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
BHVN	$1.38B	23	4.3	3.0	5.0	4.8	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Biohaven Pharmaceutical Holding Co Ltd trades at $9.59. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -4.94, it sits in the distress.

Frequently asked questions

What is Biohaven Pharmaceutical Holding Co Ltd's stock price?

Biohaven Pharmaceutical Holding Co Ltd (BHVN) trades at $9.59.

Is Biohaven Pharmaceutical Holding Co Ltd overvalued?

Smart Value Score 23/100 (Grade F, Strong Sell).

What is the price target of Biohaven Pharmaceutical Holding Co Ltd (BHVN)?

The analyst target price is $22.35, representing +133.1% upside from the current price of $9.59.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-4.94 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNYSE

CurrencyUSD

Quick metrics

P/S ratio—

ROE-310.70%

Beta3.62

50D MA$9.99

200D MA$12.31

Shares out0.15B

Float0.12B

Short ratio—

Avg volume2.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

BHVN vs LLY →BHVN vs JNJ →BHVN vs ABBV →Stock screener →